Ionis Pharmaceuticals (NASDAQ:IONS) Stock Gets Price Target Trim from HC Wainwright

Ionis Pharmaceuticals (NASDAQ:IONS) had its price objective decreased by HC Wainwright from $100.00 to $70.00 in a research report issued on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright‘s price target suggests a potential upside of 125.81% from the stock’s previous close.

Several other equities analysts have also recently issued reports on the company. Barclays dropped their price target on Ionis Pharmaceuticals from $90.00 to $85.00 and set an “overweight” rating on the stock in a research report on Wednesday, September 9th. The Goldman Sachs Group lowered their target price on Ionis Pharmaceuticals from $69.00 to $56.00 and set a “neutral” rating on the stock in a research note on Tuesday, September 8th. TD Cowen reissued a “buy” rating on shares of Ionis Pharmaceuticals in a report on Tuesday, September 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a report on Thursday, October 15th. Finally, JPMorgan Chase & Co. cut their price target on Ionis Pharmaceuticals from $76.00 to $70.00 and set an “overweight” rating for the company in a research note on Tuesday, September 22nd. Nineteen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $85.33.

Ionis Pharmaceuticals Trading Down 21.4%

Shares of Ionis Pharmaceuticals stock opened at $31.00 on Tuesday. The company has a debt-to-equity ratio of 3.07, a quick ratio of 7.73 and a current ratio of 7.89. The company has a market capitalization of $5.15 billion, a P/E ratio of -8.96 and a beta of 0.43. Ionis Pharmaceuticals has a 1 year low of $27.75 and a 1 year high of $86.74. The company’s fifty day moving average is $46.20 and its two-hundred day moving average is $65.63.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its earnings results on Monday, November 9th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($1.23) by $0.57. Ionis Pharmaceuticals had a negative net margin of 64.76% and a negative return on equity of 111.08%. The business had revenue of $242.72 million during the quarter, compared to analysts’ expectations of $178.17 million. During the same period in the prior year, the company earned ($0.80) earnings per share. The business’s revenue was up 54.8% compared to the same quarter last year. Analysts forecast that Ionis Pharmaceuticals will post -3.62 earnings per share for the current year.

Insider Transactions at Ionis Pharmaceuticals

In related news, EVP Shannon Devers sold 1,357 shares of the stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $43.54, for a total transaction of $59,083.78. Following the completion of the transaction, the executive vice president directly owned 17,811 shares of the company’s stock, valued at $775,490.94. This represents a 7.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 1.81% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Ionis Pharmaceuticals

Large investors have recently modified their holdings of the business. Handelsbanken Fonder AB boosted its position in Ionis Pharmaceuticals by 79.1% during the second quarter. Handelsbanken Fonder AB now owns 383,211 shares of the company’s stock worth $30,385,000 after acquiring an additional 169,300 shares during the last quarter. Empowered Funds LLC raised its holdings in Ionis Pharmaceuticals by 318.1% in the 1st quarter. Empowered Funds LLC now owns 103,141 shares of the company’s stock valued at $7,745,000 after acquiring an additional 78,470 shares during the last quarter. TimesSquare Capital Management LLC purchased a new position in shares of Ionis Pharmaceuticals during the 2nd quarter worth $48,690,000. Perceptive Advisors LLC purchased a new position in shares of Ionis Pharmaceuticals during the 1st quarter worth $37,845,000. Finally, Eagle Health Investments LP acquired a new stake in shares of Ionis Pharmaceuticals during the second quarter worth $15,428,000. 93.86% of the stock is owned by hedge funds and other institutional investors.

Ionis Pharmaceuticals News Roundup

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue increased 54.8% year over year to $242.7 million, exceeding analysts’ expectations, while the $0.66-per-share loss was narrower than the $1.23 loss forecast. Read More.
• Positive Sentiment: DAWNZERA sales rose 40% to $37 million in the quarter, offering evidence of growth in another commercial product. Read More.
• Neutral Sentiment: Ionis issued 2026 total revenue guidance of $875 million to $900 million, below analysts’ $920.8 million consensus estimate; the company also reaffirmed its full-year guidance. Read More.
• Negative Sentiment: The main concern is TRYNGOLZA: Ionis cut its 2026 sales outlook to about $50 million, down from its prior $100 million–$110 million target, citing a slower launch. The sharp reduction raises doubts about the drug’s near-term commercial potential and overshadowed the earnings beat. Read More.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases.

Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.